Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Infection
Erschienen in: Infection 1/2016

01.02.2016 | Erratum

Erratum to: Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project

verfasst von: Anil Mor, Trine Frøslev, Reimar Wernich Thomsen, Alessandro Oteri, Peter Rijnbeek, Tania Schink, Edeltraut Garbe, Serena Pecchioli, Francesco Innocenti, Irene Bezemer, Elisabetta Poluzzi, Miriam C. Sturkenboom, Gianluca Trifirò, Mette Søgaard

Erschienen in: Infection | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Excerpt

Appendix Table 5 in the original version of this article unfortunately contained a mistake. The overall age- and sex standardized annual prevalence of antibiotic use as shown in Table 5 was inadvertently based on partial data. We would like to correct the erroneous numbers. All changes are reflected in the revised table presented here.
Table 5
Age- and sex-standardized annual prevalence of antibiotic use per 1000 person-years according to antibiotic chemical substances
   
Denmark (AUH)
Italy (ERD)
Italy (HSD)
Germany (GePaRD)
The Netherlands (PHARMO)
The United Kingdom (THIN)
Overall
 
396.2
442.0
398.8
401.9
232.8
162.4
J01GB06
Amikacin
–
0.2
0.2
<0.1
<0.1
<0.1
J01CA04
Amoxicillin
20.2
48.9
47.8
47.8
35.2
–
J01CR02
Amoxicillin and enzyme inhibitor
1.2
94.4
75.9
7.3
27.1
21.6
J01CA01
Ampicillin
0.1
1.4
3.2
0.6
<0.1
0.7
J01CR01
Ampicillin and enzyme inhibitor
–
0.2
1.4
<0.1
–
–
J01CA51
Ampicillin, combinations
–
–
–
–
–
2.8
J01CE04
Azidocillin
–
–
–
<0.1
–
–
J01FA10
Azithromycin
22.6
35.1
25.7
21.3
12.8
1.3
J01DF01
Aztreonam
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
J01CA06
Bacampicillin
<0.1
1.8
4.6
–
–
<0.1
J01CE08
Benzathine benzylpenicillin
–
0.3
0.3
0.1
0.4
–
J01CE10
Benzathine phenoxymethylpenicillin
–
–
–
<0.1
–
–
J01CE01
Benzylpenicillin
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
J01EA02
Brodimoprim
–
–
<0.1
–
–
–
J01CA03
Carbenicillin
–
–
<0.1
–
–
<0.1
J01DC04
Cefaclor
–
1.5
1.4
7.5
0.1
5.2
J01DB05
Cefadroxil
–
0.1
<0.1
1.6
–
1.0
J01DB01
Cefalexin
<0.1
1.1
1.4
1.0
0.1
19.6
J01DB03
Cefalotin
–
–
<0.1
–
<0.1
–
J01DC03
Cefamandole
–
<0.1
<0.1
–
<0.1
–
J01DB07
Cefatrizine
–
–
<0.1
–
–
–
J01DB04
Cefazolin
–
0.4
0.4
<0.1
<0.1
<0.1
J01DD16
Cefditoren
–
0.9
1.0
–
–
–
J01DE01
Cefepime
–
0.1
0.3
<0.1
–
–
J01DD10
Cefetamet
–
<0.1
<0.1
–
–
–
J01DD08
Cefixime
–
20.1
11.8
6.5
–
0.2
J01DC09
Cefmetazole
–
–
<0.1
–
–
–
J01DD09
Cefodizime
–
0.2
0.6
–
–
–
J01DC06
Cefonicide
–
0.8
1.8
–
–
–
J01DD12
Cefoperazone
–
<0.1
<0.1
–
–
–
J01DD01
Cefotaxime
–
0.3
0.5
<0.1
<0.1
<0.1
J01DC07
Cefotiam
–
–
–
<0.1
–
–
J01DC01
Cefoxitin
–
<0.1
–
<0.1
–
–
J01DD13
Cefpodoxime
–
4.3
2.2
4.1
<0.1
<0.1
J01DC10
Cefprozil
–
1.8
1.9
–
–
<0.1
J01DB09
Cefradine
–
–
<0.1
–
<0.1
3.1
J01DD02
Ceftazidime
<0.1
0.6
1.3
<0.1
<0.1
<0.1
J01DB12
Ceftezole
–
<0.1
<0.1
–
–
–
J01DD14
Ceftibuten
–
6.3
3.9
2.6
0.1
<0.1
J01DD07
Ceftizoxime
–
<0.1
0.1
–
–
–
J01DD04
Ceftriaxone
<0.1
10.4
8.8
0.3
<0.1
<0.1
J01DC02
Cefuroxime
<0.1
3.1
2.5
14.8
0.2
0.5
G01AA05
Chloramphenicol
–
<0.1
0.1
–
–
–
J01BA01
Chloramphenicol
–
–
0.1
<0.1
<0.1
<0.1
J01AA03
Chlortetracycline
–
–
<0.1
–
–
<0.1
J01MB06
Cinoxacin
–
0.3
0.5
<0.1
–
<0.1
J01MA02
Ciprofloxacin
0.4
33.8
25.3
35.9
9.0
12.0
J01FA09
Clarithromycin
9.6
41.7
32.2
23.5
12.9
11.5
G01AA10
Clindamicin
<0.1
<0.1
0.2
0.8
<0.1
0.5
J01FF01
Clindamycin
<0.1
0.1
0.1
27.4
1.4
0.2
J01XX03
Clofoctol
–
–
<0.1
–
–
–
J01AA11
Clomocycline
–
–
–
–
–
<0.1
J01CF02
Cloxacillin
–
–
–
–
<0.1
<0.1
A07AA10
Colistin
–
–
<0.1
<0.1
<0.1
<0.1
J01XB01
Colistin
<0.1
<0.1
<0.1
<0.1
<0.1
0.1
J01CA20
Combinations
–
–
–
–
–
<0.1
J01CE30
Combinations
–
–
<0.1
0.1
0.1
<0.1
J01CR50
Combinations of penicillins
–
–
<0.1
0.5
–
–
J01AA20
Combinations of tetracyclines
–
–
–
–
–
0.3
J04AB01
Cycloserine
–
–
–
–
–
<0.1
J01XX09
Daptomycin
–
–
–
<0.1
<0.1
<0.1
J01AA01
Demeclocycline
–
–
<0.1
–
<0.1
<0.1
J01CF01
Dicloxacillin
30.1
–
–
<0.1
<0.1
–
J01AA02
Doxycycline
0.1
2.3
2.4
38.7
49.3
12.5
J01MA04
Enoxacin
–
<0.1
0.1
1.4
–
–
J01DH03
Ertapenem
–
–
<0.1
<0.1
<0.1
<0.1
J01FA01
Erythromycin
16.8
0.9
1.4
3.6
2.4
–
J04AK02
Ethambutol
<0.1
<0.1
<0.1
0.1
0.1
<0.1
J04AM03
Ethambutol and isoniazid
–
<0.1
<0.1
–
–
–
J01MA08
Fleroxacin
–
–
–
<0.1
–
–
J01CF05
Flucloxacillin
0.2
<0.1
0.2
0.6
9.1
34.2
J01FA14
Flurithromycin
–
0.1
0.3
–
–
–
J01XX01
Fosfomycin
–
20.8
18.6
1.5
0.3
<0.1
R02AB03
Fusafungine
–
<0.1
2.3
<0.1
–
–
J01XC01
Fusidic acid
0.3
–
–
–
<0.1
0.1
J01MA16
Gatifloxacin
–
–
–
<0.1
–
–
J01GB03
Gentamicin
<0.1
0.3
0.7
0.2
<0.1
<0.1
R02AB30
Gramicidin
–
–
–
–
<0.1
–
J01MA11
Grepafloxacin
–
–
–
–
<0.1
–
J01DH51
Imipenem and enzyme inhibitor
–
<0.1
0.1
<0.1
<0.1
<0.1
J04AC01
Isoniazid
<0.1
0.1
0.1
<0.1
0.2
<0.1
J04AC51
Isoniazid, combinations
–
–
–
0.1
–
<0.1
J01FA07
Josamycin
–
0.4
0.7
<0.1
–
–
J01GB04
Kanamycin
–
–
–
–
<0.1
–
A02BD07
Lansoprazole amoxicillin and clarithromycin
–
–
–
–
–
1.0
J01MA12
Levofloxacin
–
32.5
27.3
12.4
1.6
0.5
J01FF02
Lincomycin
–
0.4
4.5
<0.1
<0.1
–
J01XX08
Linezolid
<0.1
–
<0.1
<0.1
<0.1
<0.1
J01MA07
Lomefloxacin
–
2.5
2.8
–
–
–
J01DC08
Loracarbef
–
–
–
0.7
<0.1
–
J01AA04
Lymecycline
0.1
0.8
0.3
–
–
1.8
J01XX06
Mandelic acid
–
–
–
–
<0.1
–
J01CA11
Mecillinam
<0.1
–
–
–
–
–
G01AA09
Mepartricin
–
–
<0.1
–
–
–
J01DH02
Meropenem
<0.1
–
<0.1
<0.1
<0.1
<0.1
J01AA05
Metacycline
–
<0.1
<0.1
–
–
–
J01XX05
Methenamine
0.1
–
–
<0.1
0.1
<0.1
J01XD01
Metronidazole
<0.1
<0.1
<0.1
<0.1
0.1
9.6
J01CA10
Mezlocillin
–
<0.1
<0.1
<0.1
–
–
J01FA03
Midecamycin
–
<0.1
<0.1
–
–
–
J01AA08
Minocycline
–
1.8
2.1
3.7
3.0
3.0
J01FA11
Miocamycin
–
0.8
1.0
–
–
–
J01MA14
Moxifloxacin
0.1
7.0
6.7
11.2
1.4
0.2
J01MB02
Nalidixic acid
–
–
0.1
–
–
0.1
G01AA02
Natamycin
–
–
–
–
–
<0.1
A07AA01
Neomycin
–
–
–
–
<0.1
<0.1
J01GB05
Neomycin
–
–
–
–
<0.1
<0.1
A07AA51
Neomycin, combinations
–
<0.1
0.8
–
–
–
J01GB07
Netilmicin
<0.1
0.1
0.3
<0.1
<0.1
<0.1
J01XE01
Nitrofurantoin
7.0
0.1
1.1
3.7
21.7
4.6
J01XX07
Nitroxoline
–
–
–
0.9
–
–
J01MA06
Norfloxacin
<0.1
4.9
6.5
7.6
7.2
0.7
A07AA02
Nystatin
4.1
2.6
3.3
0.9
–
–
J01MA01
Ofloxacin
<0.1
0.2
0.4
6.8
2.1
0.8
J01CF04
Oxacillin
–
<0.1
<0.1
<0.1
–
–
J01MB05
Oxolinic acid
–
–
<0.1
–
–
–
J01AA06
Oxytetracycline
0.1
–
–
–
<0.1
10.3
J01AA56
Oxytetracycline, combinations
–
–
–
4.9
–
–
A02BD04
Pantoprazole, amoxicillin and clarithromycin
–
–
–
2.1
1.3
–
A07AA06
Paromomycin
–
1.0
1.2
<0.1
<0.1
–
J01MA03
Pefloxacin
–
0.9
1.0
–
–
–
J01CE06
Penamecillin
–
–
–
–
–
<0.1
J01RA01
Penicillins, combinations with other antibacterials
–
–
<0.1
–
–
–
J01CE05
Pheneticillin
–
–
–
–
8.4
–
J01CE02
Phenoxymethylpenicillin
161.9
–
0.1
30.8
2.4
–
J01MB04
Pipemidic acid
–
1.5
2.4
<0.1
0.5
–
J01CA12
Piperacillin
<0.1
0.1
0.1
<0.1
<0.1
<0.1
J01CR05
Piperacillin and enzyme inhibitor
<0.1
0.4
0.2
<0.1
<0.1
<0.1
J01MB03
Piromidic acid
–
–
<0.1
–
–
–
J01CA02
Pivampicillin
24.2
–
–
–
–
0.2
J01CA08
Pivmecillinam
33.3
–
–
–
–
0.1
J01XB02
Polymyxin b
–
–
–
–
<0.1
–
J01CE09
Procaine benzylpenicillin
<0.1
–
–
–
–
<0.1
J01CE03
Propicillin
–
–
–
1.5
–
–
J04AD01
Protionamide
–
–
–
<0.1
–
<0.1
J01MA17
Prulifloxacin
–
7.2
5.3
–
–
–
J04AK01
Pyrazinamide
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
J04AB04
Rifabutin
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
J04AB02
Rifampicin
0.1
0.4
0.5
0.2
0.2
0.2
J04AM02
Rifampicin and isoniazid
–
<0.1
<0.1
<0.1
<0.1
0.1
J04AM05
Rifampicin, pyrazinamide and isoniazid
–
<0.1
<0.1
<0.1
–
–
J04AM06
Rifampicin, pyrazinamide, ethambutol and isoniazid
–
<0.1
<0.1
–
<0.1
–
J04AB03
Rifamycin
–
<0.1
0.2
–
–
–
A07AA11
Rifaximin
–
22.4
19.4
<0.1
–
–
J01FA12
Rokitamycin
–
1.7
2.8
–
–
–
J01FA06
Roxithromycin
19.7
4.5
4.2
26.4
0.7
–
J01MA10
Rufloxacin
–
0.5
0.2
–
–
–
J01XX04
Spectinomycin
–
<0.1
<0.1
<0.1
–
–
J01FA02
Spiramycin
<0.1
4.2
6.1
0.2
0.1
<0.1
J01GA01
Streptomycin
–
<0.1
<0.1
<0.1
–
<0.1
J01EC02
Sulfadiazine
–
<0.1
<0.1
<0.1
<0.1
<0.1
J01EE06
Sulfadiazine and tetroxoprim
–
–
<0.1
<0.1
–
–
J01EE02
Sulfadiazine and trimethoprim
<0.1
–
<0.1
–
–
–
J01ED01
Sulfadimethoxine
–
–
–
–
–
<0.1
J01EB05
Sulfafurazole
–
–
–
–
<0.1
–
J01ED02
Sulfalene
–
–
<0.1
–
–
<0.1
J01ED09
Sulfamazone
–
–
<0.1
–
–
–
J01EE07
Sulfamerazine and trimethoprim
–
–
–
0.1
–
–
J01EB02
Sulfamethizole
36.3
–
–
–
<0.1
–
J01EC01
Sulfamethoxazole
–
–
–
–
<0.1
–
J01EE01
Sulfamethoxazole and trimethoprim
0.1
6.9
8.3
31.5
7.2
0.2
J01ED05
Sulfamethoxypyridazine
–
–
–
–
–
<0.1
J01EE04
Sulfamoxole and trimethoprim
–
–
–
–
–
<0.1
J01EB04
Sulfapyridine
–
–
–
–
<0.1
<0.1
J01EB07
Sulfathiazole
–
–
–
–
<0.1
–
J01RA02
Sulfonamides, combinations with other antibacterials (excl. Trimethoprim)
–
–
–
<0.1
–
–
J01CR04
Sultamicillin
–
<0.1
<0.1
2.4
–
–
J01CA15
Talampicillin
–
–
–
–
–
<0.1
J01XA02
Teicoplanin
<0.1
0.1
0.1
<0.1
<0.1
<0.1
J01FA15
Telithromycin
–
1.1
1.3
0.7
–
<0.1
J01MA05
Temafloxacin
–
<0.1
0.1
–
–
<0.1
J01CA17
Temocillin
–
–
–
–
–
<0.1
J04AK03
Terizidone
–
–
–
<0.1
–
–
J01AA07
Tetracycline
0.6
<0.1
0.1
0.7
0.9
1.0
J01BA02
Thiamphenicol
–
<0.1
2.5
–
–
–
J01CA13
Ticarcillin
–
–
–
–
–
<0.1
J01CR03
Ticarcillin and enzyme inhibitor
–
–
<0.1
–
–
<0.1
J01AA12
Tigecycline
–
–
<0.1
<0.1
<0.1
–
J01XD02
Tinidazole
–
–
–
–
–
0.1
J01GB01
Tobramycin
<0.1
0.1
0.3
<0.1
<0.1
<0.1
J01EA01
Trimethoprim
6.9
–
<0.1
1.9
12.6
–
J01MA13
Trovafloxacin
–
–
–
–
<0.1
–
R02AB02
Tyrothricin
–
<0.1
0.1
<0.1
–
–
A07AA09
Vancomycin
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
J01XA01
Vancomycin
<0.1
–
<0.1
0.1
<0.1
<0.1
Annual prevalence is expressed per 1000 person-years and is calculated by adding the number of individuals exposed to the antibiotic compound for at least 1 day divided by the total persons in the study and divided by the number of years of observation
AUH Aarhus University Hospital, ERD Emilia-Romagnia regional database, GePaRD German Pharmacoepidemiological Research Database, THIN the health initiative network
…
Metadaten
Titel
Erratum to: Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project
verfasst von
Anil Mor
Trine Frøslev
Reimar Wernich Thomsen
Alessandro Oteri
Peter Rijnbeek
Tania Schink
Edeltraut Garbe
Serena Pecchioli
Francesco Innocenti
Irene Bezemer
Elisabetta Poluzzi
Miriam C. Sturkenboom
Gianluca Trifirò
Mette Søgaard
Publikationsdatum
01.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 1/2016
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-015-0835-1

Weitere Artikel der Ausgabe 1/2016

Infection 1/2016 Zur Ausgabe

Original Paper

Intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease’s lymphadenitis

Correspondence

Response to comment on: “antibiotic use varies substantially among adults—a cross‑national study from five European Countries in the ARITMO project”

Case Report

Chronic herpes simplex type-1 encephalitis with intractable epilepsy in an immunosuppressed patient

Correspondence

Comment on: “antibiotic use varies substantially among adults: a cross-national study from five European countries in the ARITMO project”

Images in Infection

Fournier’s gangrene: a surgical emergency

Case Report

Rapid regression of Kaposi’s sarcoma of the hard palate under therapy with boosted elvitegravir-containing fixdose antiretroviral combination therapy

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise